How Should Labels and Instructions for Active Medical Devices Be Localized for Overseas Registration?

Key Summary

A practical guide for medical device manufacturers on localizing labels and instructions for active medical devices during overseas registration, covering regulatory classification, documentation reuse, common pitfalls, and AIMEILI's recommendations.

This article focuses on the localization of labels and instructions for use (IFU) of active medical devices during overseas registration. It is not a simple translation task but a systematic conversion based on the target country's regulations, product risk classification, and registration pathway. The content is compiled from AIMEILI's registration practice database, medical device international registration knowledge base, and public regulatory information. For specific projects, always refer to the latest requirements of the target country's regulatory authority and the product's technical documentation.

Key Summary

For overseas registration of active medical devices, the localization of labels and IFU is not merely a matter of translation. It requires systematic adaptation based on the target country's regulations, product risk classification, and the chosen registration pathway. Manufacturers should first determine whether the product falls under the target country's medical device regulatory scope, then confirm the risk classification and registration pathway. Next, they should evaluate whether existing technical documentation and quality system records, such as NMPA, CE, FDA, ISO 13485, and MDSAP, can be reused.

Localization must address language, units of measurement, symbols, warnings, registration certificate numbers, manufacturer and local agent information, intended use environment, electrical safety, electromagnetic compatibility, and wireless communication requirements. Common risks include blindly copying English or Chinese content, failing to consider local clinical evaluation requirements, inconsistencies with the registration technical file, and not linking post-market adverse event reporting with label updates.

Enterprises should establish a process of "core technical documentation reuse plus localized conversion," with local agents or authorized representatives reviewing label drafts. Labels and IFU should be updated simultaneously during registration changes, renewal, and safety alert releases.

Applicable Scenarios and Core Questions

During overseas registration of active medical devices, the localization of labels and IFU is often underestimated. The labels and IFU submitted in the registration dossier must comply with the target country's medical device regulations and support the evaluation of safety and effectiveness. Localization here is not the same as language conversion.

Applicable scenarios include:

Registration in GHWP member countries, such as multi-country registrations in Southeast Asia, the Middle East, and Latin America;
Converting existing NMPA registrations or CE certifications into target country submission files;
OEM/ODM manufacturing, where label and IFU branding, manufacturer, and responsible party information must be confirmed;
Renewal, variation, or label updates for existing certificates.

The core question is: how can manufacturers determine the target country's specific requirements for labels and IFU, convert the evidence in existing technical documentation into locally acceptable submission documents, and ensure that post-market label maintenance remains synchronized with adverse events and safety alerts?

Registration Assessment Logic

Step 1: Determine Regulatory Scope

First, assess whether the product falls within the target country's medical device regulatory scope. For example, some countries define in vitro diagnostic devices, home-use active devices, and wireless medical devices differently. If the product has Bluetooth or Wi-Fi capabilities, radio regulations and cybersecurity requirements must also be considered.

Step 2: Determine Risk Classification and Registration Pathway

Classify the product as Class I, II, or III according to the target country's risk classification rules. Confirm whether the pathway is self-declaration, registration, pre-market notification, or pre-market approval. The applicant is typically the local manufacturer or authorized representative, and the name and address of the applicant must appear on the label and IFU.

Step 3: Assess Reusability of Existing Documentation

If you already hold an NMPA registration certificate, CE technical documentation, FDA 510(k) or PMA, ISO 13485 certificate, or MDSAP certificate, verify item by item whether the target country accepts these documents, and whether local language versions, specific warnings, or clinical evaluation data are required.

Step 4: Confirm Full Requirements

Confirm all requirements for technical documentation, performance verification, risk management, clinical evaluation or clinical evidence, labels and IFU, local agent, authorized representative, and post-market maintenance. For the quality system, verify that it covers label control, IFU revisions, adverse event reporting, and recall procedures. For GHWP member countries and multi-country registration scenarios, a "core documentation library plus country-specific difference matrix" approach is recommended to avoid starting translation and verification from scratch in each country.

Documentation and Evidence

Documentation that needs to be prepared for label and IFU localization includes:

Product label drafts, including labels for the smallest sales unit, transport labels, and packaging labels;
Instructions for use, including operating instructions, maintenance, troubleshooting, and disposal;
Quick guides or patient cards, if the product is used directly by patients;
Information on the sales packaging.

For technical evidence, the following should be provided:

Product standards or performance specifications;
EMC and electrical safety test reports;
Software validation and cybersecurity statements;
Biocompatibility test reports;
Intended purpose, indications, and contraindications described in the risk management report;
Clinical evaluation reports or clinical evidence.

All descriptions in the labels and IFU must be consistent with this evidence. Manufacturers should also prepare translations into the target country's language and have them reviewed by a certified local translator or local agent. Units of measurement must follow local conventions, such as metric or SI units. The name, address, and registration information of the local agent or authorized representative must be included.

For multi-country registrations, it is recommended to establish a change control record for labels and IFU, clearly showing which content originates from the original technical documentation, what has been locally modified, and the reason for differences between country versions.

Common Errors

Using Chinese or English labels and IFU with only superficial translation, without considering local regulatory requirements for symbols, colors, warnings, and units of measurement.
Inconsistency between the label/IFU content and the intended purpose, performance specifications, or contraindications in the registration application, leading to deficiency letters or post-market audit failures.
Ignoring local requirements for the "medical device" symbol, registration certificate number, manufacturer, local agent, and adverse event reporting contact details, resulting in incomplete labels.
Failing to include IFU updates in the quality system's design change control process, so labels and IFU are not revised after safety alerts are issued.
For home-use or patient self-use active devices, not using locally understandable language and icons, or not making safety warnings prominent, leading to user errors.
Overlooking radio type approval or cybersecurity labeling requirements, such as wireless certification marks or software version numbers.

Enterprise Preparation Checklist

Confirm the target country's regulatory classification and registration pathway, and obtain local technical guidance or regulatory checklists.
Compile an inventory of existing NMPA, CE, FDA, ISO 13485, and MDSAP documents and assess the reusability of each.
Establish a label and IFU localization team including R&D, regulatory affairs, registration, quality, clinical, and translation personnel.
Create a target country standard difference table covering language, units of measurement, symbols, warnings, agent information, registration certificate numbers, and other differences.
Complete initial translation and internal review of labels and IFU, cross-checking the intended purpose and performance data in the registration technical files.
Engage a local agent or professional regulatory consultancy in the target country to review the drafts and ensure compliance with local regulatory practice and review expectations.
Establish design input, design output, review, and change control records for labels and IFU within the quality system.
Develop a post-market information update plan linking adverse events, safety alerts, recalls, and IFU revisions.

AIMEILI's Perspective

The most common misjudgment by manufacturers is believing that translation equals localization. In reality, reviewers in the target country will closely check whether the intended purpose, target population, warnings, and precautions in the labels and IFU are consistent with the descriptions in the registration evidence. Ambiguities or omissions caused by translation frequently lead to deficiency responses.

At the early stage of a project, a regulatory gap analysis of the target country should be prioritized, rather than immediately starting translation. First clarify the product classification, registration pathway, applicant, and local agent requirements. Then assess which parts of existing NMPA, CE, FDA, ISO 13485, and MDSAP documentation can be reused and which must be localized. If the structure, terminology, and symbols of labels and IFU are directly adopted from the English version, issues may arise in countries with specific medical practices or regulatory systems.

Reusable documentation includes product performance data, electrical safety test reports, EMC reports, basic risk analysis from the risk management report, and clinical evidence. Items that must be localized include language, local regulatory marks, warnings, agent information, and adverse event reporting procedures. The label control procedures in the quality management system should also be revised to meet the target country's requirements.

Local agents, certificate control, changes, and renewals are extremely important. The local agent is responsible for communication with the regulatory authority and post-market reporting. If the manufacturer does not have a local entity, it must rely on the agent. If the control of registration certificates and labels is unclear, especially when agents change or partnerships terminate, the agent information on the label may become invalid. During changes and renewals, labels and IFU must be updated simultaneously; otherwise, certificates may be suspended or products may be detained.

For multi-country registration, a unified core documentation library should be established, extracting technical data and a base label template common to all countries, and then quickly generating country-specific versions through a difference matrix. This reduces duplicate rework and deficiency risks and facilitates unified post-market maintenance.

Common Follow-up Questions

Must label and IFU localization be completed by a translation agency in the target country?

Most countries require a translation in the local official language but do not mandate that it be done by a local translation agency. The key is that the translation must be accurate and be reviewed by a local agent or specialized institution. For professional medical terminology and warning statements, it is recommended to use specialized medical device translation services and add a review step to reduce the risk of language ambiguity.

Can CE-certified labels and IFU be used directly for registration in Southeast Asian countries?

No. Although the performance data and risk management report in the CE technical documentation can be reused, countries in Southeast Asia may have their own label requirements, languages, units of measurement, registration certificate number formats, and local agent information. Even for the same product, labels and IFU must be converted according to the target country's regulations, not simply by changing the language version.

What should be noted for labels and IFU if the product uses wireless communication technology?

In addition to medical device regulations, radio certification requirements in the target country must be satisfied. The label may need to indicate the radio type approval mark, transmission frequency, and maximum output power. The IFU should include wireless communication interference warnings, cybersecurity settings, and electromagnetic compatibility precautions. Manufacturers should confirm with the local agent whether a separate radio certification is required, as this is often overlooked.

Continue Reading

Previous: How to handle inconsistency in quality system certificates for overseas registration of sterile consumables?

Next: How to prepare clinical evaluation documentation for overseas registration of active medical devices?

Need a registration pathway assessment?

Send product type, intended use, target countries and existing certificates. AIMEILI can help evaluate registration pathway, documentation gaps and compliance risks.

Contact AIMEILI